Most read articles by the same author(s)
- Gian Piero Perna, Roberto Ravasio, Antonio Ricciardelli, Budget impact analysis of ticagrelor for preventive treatment of patients with acute coronary syndromes , Global and Regional Health Technology Assessment: Vol. 4 No. 1 (2017): January-December 2017
- Clement Tournier, Valerie Deroo, Sara Villa, Giovanni Giuliani, Carlo Lucioni, Silvio Mazzi, Roberto Ravasio, An Approach to Evaluate Payment-by-Results Agreements , Global and Regional Health Technology Assessment: Vol. 3 No. 2 (2016): May-August 2016
- Roberto Ravasio, Giovanni Rosti, Cost-consequence analysis of aprepitant compared to standard therapy (5-HT3 + corticosteroids) for the prevention of highly emetogenic chemotherapy-induced nausea and vomit , Global and Regional Health Technology Assessment: Vol. 2 No. 2 (2015): May-August 2015
- Roberto Ravasio, Mauro Maresca, Barbara Busà, Benedetto Maurizio Celesia, Budget impact analysis in the maintenance raltegravir-containing regimen in virologically suppressed HIV infected patients , Global and Regional Health Technology Assessment: Vol. 4 No. 1 (2017): January-December 2017
- Roberto Ravasio, Roberto Giacomelli, Stefano Bianchi, Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease , Global and Regional Health Technology Assessment: Vol. 7 No. 1 (2020): January-December 2020
- Roberto Ravasio, Fabio Rigo, Emanuela Lattuada, Ercole Concia, Massimiliano Lanzafame, Economic Evaluation of Nevirapine plus Raltegravir as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1 Infected Patients , Global and Regional Health Technology Assessment: Vol. 3 No. 2 (2016): May-August 2016
- Roberto Ravasio, Andrea Marcellusi, Luca De Nicola, Economic impact of dapagliflozin in the management of chronic kidney disease in Italy: results from a micro-simulation model , Global and Regional Health Technology Assessment: Vol. 11 No. 1: January-December 2024
- Luca Stingeni, Roberto Ravasio, Chiara Palladino, Sara Di Fino, Anna Levi, Gianluca Ronci, Paolo Gisondi, Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy , Global and Regional Health Technology Assessment: Vol. 12 No. 1 (2025): January-December 2025
- Roberto Ravasio, Economic Impact of Therapeutic Choices: The Case of Incretins , Global and Regional Health Technology Assessment: Vol. 1 No. 2 (2014): July-December 2014